Showing results (1321-1330 of 5,587) with videos related to

Sort By:
Pageof 559
Nuclear Medicine Communications|February 5, 2024
[ 18 F]-PSMA-1007 PET imaging optimization and inter-rater reliability - a comparison of three different reconstructions read by four radiologistsOlof Jonmarker, Ted Nilsson, Rimma Axelsson, et al.
Nuclear Medicine Communications|May 15, 2024
Correlates of markers of dyssynchrony in patients with STEMI and multivessel disease: an analysis from the IAEA SPECT STEMI trialAmalia Peix, Amelia Jimenez-Heffernan, Niveditha Devasenapathy, et al.
Nuclear Medicine Communications|May 10, 2024
Retrospective study of qualitative assessment in detecting synchronous and metachronous malignancies in adult cancer patients by 18 F-FDG PET/CTJeremy Hugh Yen-Hey Lau, Koon Kiu Ng, Wai Chung Wong, et al.
Nuclear Medicine Communications|April 30, 2024
Can 18 F FDG PET/CT metabolic parameters be used to noninvasively differentiate between different histopathological subtypes and Fuhrman grades of renal cell cancer?Yash Jain, Archi Agrawal, Amit Joshi, et al.
Nuclear Medicine Communications|October 12, 2023
Stress-only versus rest-stress SPECT MPI in the detection and diagnosis of myocardial ischemia and infarction by machine learningFanghu Wang, Hui Yuan, Jieqin Lv, et al.
Nuclear Medicine Communications|October 6, 2023
Impact of forced diuresis at two different time points on pelvic imaging in prostatic carcinoma with 68 Ga-PSMA PET/CTShobhana Raju, Akshima Sharma, Sanjay Kumar, et al.
Nuclear Medicine Communications|October 2, 2023
Potential role of pre-treatment bone marrow SUVmean to liver SUVmean ratio (BM/L) and comparison of primary tumour FDG uptake with brain FDG uptake in predicting survival in limited-stage lung cancersSuna Kavurgaci, Özlem Özmen, Ebru Tatci, et al.
Nuclear Medicine Communications|October 2, 2023
Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized studyEmmanouil Panagiotidis, Vasiliki Fragkiadaki, Nikolaos Papathanasiou, et al.
Nuclear Medicine Communications|September 20, 2023
The tyrosine kinase inhibitor nintedanib enhances the efficacy of 90 Y-labeled B5209B radioimmunotherapy targeting ROBO1 without increased toxicity in small-cell lung cancer xenograft miceKentaro Fujiwara, Atsushi B Tsuji, Hitomi Sudo, et al.
Nuclear Medicine Communications|September 18, 2024
Predicting invasiveness of ground-glass nodules in lung adenocarcinoma: based on preoperative 18 F-fluorodeoxyglucose PET/computed tomography and high-resolution computed tomographyXimei Wang, Chunyan Yang, Xuewei Wang, et al.
Pageof 559